These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8144 related articles for article (PubMed ID: 2257565)

  • 1. Problems and prospects of new immunotherapeutic approaches.
    Fridman WH; Mathiot C; Michon J; Teillaud JL; Dorval T; Zucker JM; Pouillart P
    Cancer Detect Prev; 1990; 14(6):657-60. PubMed ID: 2257565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy of cancer using cytokinins. Use and perspectives in lung oncology].
    Moro D; Goy A; Nagy-Mignotte H; Brambilla C
    Rev Mal Respir; 1990; 7(3):195-201. PubMed ID: 1694591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment with cytokines of metastatic kidney cancer: the Lyon experience].
    Négrier S; Mercatello A; Coronel B; Lanier F; Merrouche Y; Bret M; Blay JY; Lasset C; Thiesse P; Carrie C
    Bull Cancer; 1993 Jul; 80(7):601-9. PubMed ID: 8204940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
    Lotze MT; Shurin M; Esche C; Tahara H; Storkus W; Kirkwood JM; Whiteside TL; Elder EM; Okada H; Robbins P
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S61-6. PubMed ID: 10685662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of antitumor immune responses by hematopoietic cytokines.
    Waller EK; Ernstoff MS
    Cancer; 2003 Apr; 97(7):1797-809. PubMed ID: 12655538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
    Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-based therapy and biochemotherapy for advanced melanoma.
    Atkins MB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
    Christ O; Seiter S; Matzku S; Burger C; Zöller M
    Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2.
    Talmadge JE; Black PL; Tribble H; Pennington R; Bowersox O; Schneider M; Phillips H
    Drugs Exp Clin Res; 1987; 13(6):327-37. PubMed ID: 3115744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LAK cells and immunotherapy of cancer].
    Khayat D; Weil M; Soubrane C; Jacquillat C
    Bull Cancer; 1988; 75(1):3-7. PubMed ID: 3258774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 408.